

Temporal Profile of Biofilm Formation, Gene Expression and Virulence Analysis in *Candida albicans* Strains

Patrícia Pimentel de Barros · Rodnei Dennis Rossoni · Felipe De Camargo Ribeiro · Juliana Campos Junqueira · Antonio Olavo Cardoso Jorge

Received: 5 April 2016/Accepted: 29 October 2016/Published online: 9 November 2016 © Springer Science+Business Media Dordrecht 2016

Abstract The characterization of Candida albicans strains with different degrees of virulence became very useful to understand the mechanisms of fungal virulence. Then, the objective of this study was to assess and compare the temporal profiles of biofilms formation, gene expression of ALS1, ALS3, HWP1, BCR1, EFG1, TEC1, SAP5, PLB2 and LIP9 and virulence in Galleria mellonella of C. albicans ATCC18804 and a clinical sample isolated from an HIV-positive patient (CA60). Although the CFU/mL counting was higher in biofilms formed in vitro by ATCC strain, the temporal profile of the analysis of the transcripts of the C. albicans strains was elevated to Ca60 compared to strain ATCC, especially in the genes HWP1, ALS3, SAP5, PLB2 and LIP9 (up regulation). Ca60 was more pathogenic for G. mellonella in the survival assay (p = 0.0394) and hemocytes density (p = 0.0349), agreeing with upregulated genes that encode the expression of hyphae and hydrolase genes of Ca60. In conclusion, the C. albicans strains used in this study differ in the amount of biofilm formation, virulence in vivo and transcriptional profiles of genes analyzed that can change factors associated with colonization, proliferation and survival of C. albicans at different niches. *SAP5* and *HWP1* were the genes more expressed in the formation of biofilm in vitro.

Keywords Candida albicans · Biofilms · Gene expression · Galleria mellonella

Introduction

In all countries worldwide, *Candida albicans* is the most frequently isolated species, in both superficial and invasive infections and is associated with many cases of mortality. The most affected subjects are HIV-positive individuals and patients undergoing cancer therapy, among others with compromised immune system [1–4].

The major virulence factors include the expression of adhesins and invasins on the cell surface, the morphological transformation capacity of yeast to hyphae, biofilm formation and the secretion of hydrolytic enzymes, among others [2, 5]. Among the virulence factors of *C. albicans*, the capacity to form biofilm in catheters, prostheses (abiotic) and mucosal surfaces (biotic) is one of the most important factors because it facilitates the adhesion, proliferation and spread of this microorganism to other infection sites [6, 7].

Genes *TEC1*, *BCR1* and *EFG1* are essential for the formation of a mature and stable biofilm resistant to antifungal therapy and to the protection of the immune system, allowing the spread of infections caused by

P. P. de Barros $(\boxtimes) \cdot R$. D. Rossoni \cdot

F. De Camargo Ribeiro · J. C. Junqueira · A. O. C. Jorge Departament of Biosciences and Oral Diagnosis, Institute of Science and Technology, UNESP – Univ Estadual Paulista, Av. Engenheiro Francisco José Longo 777, São José Dos Campos, SP CEP 12245-000, Brazil e-mail: barrosdnapp@yahoo.com.br

this microorganism [7-13]. Target genes, under the influence of BCR1, are described as specific hyphae genes, such as ASL1, ALS3 and HWP1, among others [11, 12]. The *EFG1* gene, an important regulatory factor of transcription in biofilm, is involved in the colonization process by C. albicans, modifying its expression according to the immune system of the host and conferring to C. albicans the capacity to transition from commensal microorganism to opportunistic pathogen status [13]. Several studies [7, 10, 12, 14] have revealed that decreased expression of genes involved in the regulation of the cell transcriptional process can usually contribute, either directly or indirectly, to the adhesion and invasion processes. Changes in the expression levels of genes involved in these functions may lead to a definite compromise of the biofilm structure, contributing to its vulnerability to both antifungal agents and the host's immune system.

Regarding the virulence factors of *C. albicans*, secreted hydrolases also play a key role in pathogenicity [15–19]. Following yeast adhesion to the host cell surface, a morphological transformation occurs and gives rise to new cells, the hyphae. These cells secrete large amounts of hydrolases, which facilitate penetration into the host cell and promote efficient nutrient acquisition [15–17]. Three different classes of these enzymes are expressed by *C. albicans*: proteases (*SAPs*), lipases (*LIPs*) and phospholipases (*PLBs*). The *SAP5*, *LIP9* and *PLB2* genes contribute to pathogenicity by means of host tissue degradation, facilitating fungal invasion [18, 19].

In vivo studies are fundamental to the study of microbial interactions of pathogenic microorganisms, and the discovery of new antimicrobial agents. An animal model should reproduce the corresponding pathogenesis of infection in humans, including colonization and invasion from a specific route of entry and interaction with the host immune system [20]. In recent decades, a large number of invertebrate models including Galleria mellonella, Caenorhabditis elegans, Drosophila melanogaster and Dictyostelium discoideum, were developed and are being used for experimental study of pathogenicity [21]. These models have provided considerable knowledge in different aspects of microbial infection and have several advantages over mammalian models, such as low cost in the design, ease of use, speed in obtaining results and the possibility of large-scale studies, serving as screening for studies on vertebrates, thus meeting the ethical and legal issues of the principle of the 3Rs (reduction, refinement and replacement) as well as the need to develop alternatives to conventional animals [22–24].

Understanding the pathogenicity mechanisms that *C. albicans* uses during infections is necessary to the development of new antifungal therapies and methodologies for accurate and rapid diagnosis. The capacity to form biofilm and hydrolase secretion is an essential factor for the maintenance of this microorganism in the environment, which render it able to resist any type of therapy or damage to its structure [6, 25, 26]. Thus, the objective of this study was to assess and compare the temporal profiles of biofilms formation, gene expression of *ALS1*, *ALS3*, *HWP1*, *BCR1*, *EFG1*, *TEC1*, *SAP5*, *PLB2* and *LIP9* and virulence in *Galleria mellonella* of reference sample *C. albicans* ATCC18804 and a clinical sample isolated from an HIV-positive patient (Ca60).

Materials and Methods

Samples

Two C. albicans samples were used in this study, ATCC18804 and a clinical isolate (Ca60) from the oral cavity of an HIV-positive patient. All strains were from the Laboratory of Microbiology of the Institute of Science and Technology São José dos Campos/ UNESP (Univ Estadual Paulista "Julio de Mesquita Filho" - UNESP), and the Ca60 strain was isolated from an oropharyngeal candidiasis lesion of an HIVpositive patient of the Emílio Ribas Infectology Institute (Instituto de Infectologia Emílio Ribas), according to approval of the Ethics Committee (Protocol 051/2009-PH/CEP). This sample was cultured in chromogenic HiCrome Candida medium (Himedia, Mumbai, India), identified by biochemical methods (API20C System- BioMérieux, Paris, France) and confirmed via molecular methods (PCR Multiplex).

Biofilm Formation

Suspensions of each *C. albicans* strain were prepared from overnight cultures in 5 mL of yeast-nitrogen base (YNB) broth (Difco Laboratories Inc, Detroit, MI, USA) at 37 °C for 18 h. Then, the cells were centrifuged at $2.000 \times g$ for 10 min, and the supernatant was discarded. The sediment was resuspended in 0.9% NaCl and mixed in shaker tubes for 30 s. This cell washing was repeated twice again. Cell densities were adjusted at 10^7 viable cells/mL using a hemocytometer.

For the biofilm formation, the methods described by Seneviratne et al. [27] and Costa et al. [28] were used with some changes. Initially, for the biofilms formation, 100 µL of the standardized microorganism suspension was pipette into each well of 96-well microtiter plates (TPP[®], Trasadingen, Switzerland). The plates were incubated under stirring at 75 rpm (Quimis, Diadema, São Paulo) at 37 °C for 90 min in the initial adhesion stage. After this period, the microorganism supernatant was gently aspirated, and each well was rinsed with 200 µL sterile 0.9% NaCl saline. Rinsing was repeated twice with sterile 0.9% NaCl saline for removal of non-adherent cells. Then, 200 µL of YNB broth (Difco Laboratories Inc, Detroit, MI, USA) supplemented with 100 mM of glucose was pipetted, and the plates were incubated at 37 °C for 12, 24 and 48 h under stirring (Quimis, Diadema, São Paulo). For the 48-h biofilm, the broth was changed after 24 h. For the 0-h time, the biofilm was removed right after the initial adhesion stage. The experiments were performed in triplicate at different times and with ten replicates per biofilm formation time, totaling 240 assays.

Biofilm Quantification

Once the formation time of the biofilms had elapsed, the content of the plates was aspirated and rinsed twice with sterile 0.9% NaCl saline. Then, 200 μ L of sterile 0.9% NaCl saline was transferred to each well, and the biofilm attached to the plate bottom was broken by homogenization for 30 s in an ultrasonic homogenizer (Vibra Cell–Sonics & Materials, Inc. Newtown, USA) with 25% amplification. A 100 μ L volume of this inoculum was transferred to 1.5 mL microtubes containing 900 μ L sterile 0.9% NaCl saline. Using the solution contained in the microtubes, decimal dilutions of the biofilm suspension were performed, from which aliquots of 100 μ L were seeded into *Petri* dishes containing chromogenic HiCrome *Candida* medium (Himedia, Mumbai, India), and the dishes

were incubated at 37 $^{\circ}\mathrm{C}$ for 48 h. After this time, the CFU/mL was calculated.

Quantitative RT-PCR

Total RNA was extracted using the TRIzol[®] kit (Ambion, Inc., Carlsbad, CA, USA) as recommended by the manufacturer. A volume of 1.0 mL TRIzol® was added to a 2.0-mL microtube containing the collected yeast and was incubated at room temperature (RT) for 10 min. Subsequently, 200 µL chloroform was added (Sigma-Aldrich, St. Louis, MO, USA), and the microtubes were centrifuged at $12.000 \times g$ for 15 min at 4 °C. The supernatant was transferred to a new microtube, and 500 µL isopropanol (Sigma-Aldrich, St. Louis, MO, USA) was added. After centrifugation, the sediment obtained was washed with 70% ethanol (Sigma-Aldrich, St. Louis, MO, USA), centrifuged again and resuspended in 50 µL RNA storage buffer (Ambion Inc., Carlsbad, CA, USA). The RNA concentration, purity and quality were checked using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA) and agarose gel electrophoresis (InvitrogenTM, Carlsbad, CA, USA). The gel was stained with ethidium bromide (InvitrogenTM, Carlsbad, CA, USA) and visualized on a transilluminator.

The total extracted RNA (2 µg) was treated with DNaseI (Turbo DNase Treatment and Removal Reagents-Ambion, Inc., Carlsbad, CA, USA) and transcribed into complementary DNA (cDNA) using the SuperScript[®]III First-Strand Synthesis SuperMix Kit for qRT-PCR (InvitrogenTM, Carlsbad, CA, USA) according to the protocols recommended by the manufacturer.

The primers for all genes analyzed in the present study were described and used in the same way as indicated by Nailis et al. [19], Nailis et al. [29] and Hnisz et al. [30], according to Table 1. Their specificity was confirmed for *C. albicans*, and not for the other species of this genus.

Transcribed cDNAs were amplified for the relative quantification of *EFG1*, *TEC1*, *BCR1*, *ALS1*, *ALS3*, *HWP1*, *SAP5*, *LIP9* and *PLB2* gene expression levels in relation to the concentration of the reference gene (*ACT1*). In our study, four reference genes, *ACT1*, *PMA1*, *RIP1* and *LSC2*, were tested in all experimental groups. The results were analyzed at http://www. leonxie.com/referencegene.phpe, and the reference gene chosen was *ACT1*. reverse (R) primers used in real-time PCR for the target and reference genes

Gene name	Sequence 5'- 3'	Reference	
ALS1	F- CAACAGGCACCTCAGCATCTAC	Nailis et al. [29]	
ALS1	R- CTCCACCAGTAACAGATCCACTAGTAA	Nailis et al. [29]	
ALS3	F- CAACTTGGGTTATTGAAACAAAAACA	Nailis et al. [29]	
ALS3	R- AGAAACAGAAACCCAAGAACAACCT	Nailis et al. [29]	
BCR1	F- AATGCCTGCAGGTTATTTGG	Hnisz et al. [30]	
BCR1	R- TTTTAGGTGGTGGTGGCAAT	Hnisz et al. [30]	
EFG1	F- CATCACAACCAGGTTCTACAACCAAT	Hnisz et al. [30]	
EFG1	R- CTACTATTAGCAGCACCACCC	Hnisz et al. [30]	
HWP1	F- GACCGTCTACCTGTGGGACAGT	Nailis et al. [19]	
HWP1	R- GCTCAACTTATTGCTATCGCTTATTACA	Nailis et al. [19]	
LIP9	F- CGCAAGTTTGAAGTCAGGAAAA	Nailis et al. [19]	
LIP9	R- CCCACATTACAACTTTGGCATCT	Nailis et al. [19]	
PLB2	F- TGAACCTTTGGGCGACAACT	Nailis et al. [19]	
PLB2	R- GCCGCGCTCGTTGTTAA	Nailis et al. [19]	
SAP5	F- CCAGCATCTTCCCGCACTT	Nailis et al. [19]	
SAP5	R- GCGTAAGAACCGTCACCATATTTAA	Nailis et al. [19]	
TEC1	F- TGAGCAACAACAACAACAACCAC	Hnisz et al. [30]	
TEC1	R- CTGGGTTGTTGTCATAGTGGCC	Hnisz et al. [30]	
ACT1	F- TTTCATCTTCTGTATCAGAGGAACTTAT	Nailis et al. [19]	
ACT1	R- ATGGGATGAATCATCAAACAAGAG	Nailis et al. [19]	
LSC2	F- CGTCAACATCTTTGGTGGTATTGT	Nailis et al. [19]	
LSC2	R- TTGGTGGCAGCAATTAAACCT	Nailis et al. [19]	
PMA1	F- TTGCTTATGATAATGCTCCATACGA	Nailis et al. [19]	
PMA1	R- TACCCCACAACTTGGCAAGT	Nailis et al. [19]	
RIP1	F- TGTCACGGTTCCCATTATGATATTT	Nailis et al. [19]	
RIP1	R- TGGAATTTCCAAGTTCAATGGA	Nailis et al. [19]	

The qPCR method assessed the amount of cDNA produced in the exponential phase of the amplification reaction. For the detection system, the SYBR[®]Green fluorophore was used (Platinum[®] SYBR[®] Green qPCR SuperMix-UDG Applied Biosystems, Framingham, MA, USA), which consisted of the following reaction: 10 µL Supermix Platinum SYBR Green, 1 µL ROX (reference dye), 300 nM forward primer, 300 nM reverse primer, 3.4 µL cDNA solution (diluted 1:5) and 4.6 µL Ultrapure water (InvitrogenTM, Carlsbad, CA, USA). These reactions were assembled in a 96-well plate (InvitrogenTM, Carlsbad, CA, USA) to a final volume of 20 µL in each well. For the negative control, all reagents except for cDNA were added to the last wells of the plate, which was then sealed with optical adhesive (InvitrogenTM, Carlsbad, CA, USA). Subsequently, the plate was placed in a StepOnePlusTM PCR System (Applied Biosystems, Framingham, MA, USA) and was run on the following cycle: 50 °C for 2 min, followed by initial denaturation at 95 °C for 2 min, and 40 cycles at 95 °C for 15 s and 60 °C for 30 s. After the last cycle, the dissociation curve (melt curve) of the samples was analyzed, and the absence of any bimodal curve or abnormal amplification signal was verified every 0.1 °C. The $2^{-\Delta\Delta CT}$ method was used to analyze relative changes in the gene expression based on the qPCR experiment [31].

G. mellonella Survival

G. mellonella were infected with *C. albicans* as previously described by Cotter et al. [32] and Junqueira et al. [26]. In brief, *G. mellonella* caterpillars in the final instar larval stage were stored in the dark and used within 7 days from the date of shipment.

Sixteen randomly chosen caterpillars (330 \pm 25 mg) were infected for each *Candida* isolate.

C. albicans inocula were prepared by growing 50 mL YPD cultures overnight at 30 °C. Cells were pelleted at 1.300 Xg for 10 min followed by three washes in PBS. Cell densities were determined by hemocytometer count. *Candida* inocula were confirmed by determining the colony-forming units per milliliter (CFU/mL) on YPD.

A Hamilton syringe was used to deliver *Candida* inocula at 10^6 cells/larvae in a 10 µL volume into the hemocoel of each larva via the last left proleg. Before injection, the area was cleaned using an alcohol swab. After injection, larvae were incubated in plastic containers (37 °C), and the number of dead *G. mellonella* was scored after 4, 8, 12 and 24 h post-infection. Larvae were considered dead when they displayed no movement in response to touch.

Effects of *C. albicans* Infection to *G. mellonella* Hemocyte Density

Larvae were infected with *C. albicans* by injecting the yeast at the last left pro-leg. Hemocytes were collected from the hemocoel at 4, 8 and 12 h post-injection with *C. albicans*. Larvae were bled into tubes containing cold sterile insect physiologic saline (IPS) (150 mM sodium chloride; 5 mM potassium chloride; 100 mM Tris–hydrochloride, pH 6.9 with 10 mM EDTA and 30 mM sodium citrate). The hemocytes were enumerated with the aid of a hemocytometer. We did not differentiate between the six types of hemocytes, and results were averaged from four replicates.

Statistical Analysis

The data are expressed as the means \pm standard deviations (SD) of the results obtained in each experimental group and each biofilms development time and were analyzed for normal distribution using the Kolmogorov–Smirnov test (SigmaPlotTMSystat Software, Inc., San Jose, CA, USA).The data from relative quantification of gene expression were analyzed using analysis of variance (ANOVA) and Tukey's test. Killing curves were plotted, and statistical analysis was performed by the log-rank (Mantel-Cox) test. Student's *t* test was used to compare hemocyte densities and CFU/mL assays. Statistical analysis was performed using the software GraphPad

Prism 5 (GraphPad Software, Inc., California, CA, USA). *P* value ≤ 0.05 was considered significant.

Results

In this study, the biomasses formed in in vitro biofilms from *C. albicans* ATCC18804 and Ca60 strains (isolated from oropharyngeal candidiasis) using the bottom plate method were quantified by CFU/mL count and gene expression (qRT-PCR) related to yeast virulence. In vivo we assessed the pathogenicity of the strains by infecting *G. mellonella* larvae with *Candida* strains through the survival curve and hemocytes density.

The ATCC18804 strain produced cell biomasses of 6.197; 7.442; 7.234 and 7.315 \log_{10} , respectively, at 0, 12, 24 and 48 h. A similar result was observed with the Ca60 strain; however, biomass production was lower in relation to the ATCC strain, except at time 0 h: 6.402; 6.92; 6.774 and 6.682 \log_{10} of biomass at times 0, 12, 24 and 48 h. In the comparison between the two strains, we observed a statistically significant difference for all evaluated times, 0 h (p = 0.0079), 12 h (p = 0.0001), 24 h (p = 0.0001) and 48 h (p = 0.0001) as shown in Fig. 1.

All the primers employed in this study were specific for the targeted *C. albicans* genes and amplified in the expected PCR fragment, which were subjected to agarose gel electrophoresis to confirm the molecular weight (data not shown). The efficiency of PCR amplification was between 95 and 100% for each primer tested, indicating validation of the primers and the standardization of the qPCR assays. The analysis of the obtained melting curves confirmed the presence of a single peak, demonstrating the specificity of the tested primers.

The expression levels of the adhesion genes (*ALS1*, *ALS3* and *HWP1*), transcriptional regulatory genes (*TEC1*, *BCR1* and *EFG1*), and hydrolase genes (*SAP5*, *PLB2* and *LIP9*) were quantified in the cells of the ATCC18804 and Ca60 strains at 0, 12, 24 and 48 h of biofilms development using qPCR (Fig. 2).

In the ATCC18804 strain, expression levels of the transcriptional genes at time 12 h for *TEC1*, *BCR1* and *EFG1* were significantly increased compared to the control (p = 0.0001); however, at the other times, gradual decreases were observed, with no significant differences. The *ALS1* expression levels obtained were



Fig. 1 Temporal quantification in between 0, 12, 24 and 48 h of biofilms formed by *C. albicans* strains using the viable cell quantification method (CFU/mL). Values are expressed as the means and standard deviation. *Different letters* represent significant differences between the ATCC18804 and Ca60 strains at the same time (Student's *t* test, p < 0.05)

low in relation to the control at all times analyzed. *ALS3* gene expression was higher at 12 h but not significant, and gradual and significant decreases were observed at the other times (p = 0.0001). The genes related to hydrolases (*SAP5*, *PLB2* and *LIP9*) and adherence (*HWP1*) displayed similar patterns, with gradual increases in the transcript levels over the different biofilm formation times, and a significant value (p = 0.0001) was observed only for the *PLB2* gene at 48 h (Table 2).

The Ca60 strain exhibited a different gene expression pattern compared to the ATCC strain: The values of the transcript levels of genes ALS3, HWP1, TEC1, BCR1, SAP5, PLB2 and LIP9 were much higher than those observed in the reference strain and significant (p = 0.0001) compared to the control. In addition, the HWP1 adhesion gene expression level was expressive and significant and increased gradually at all biofilm formation times compared to both the control (p = 0.0001) and the reference strain. The expression levels of the PLB2 and LIP9 genes were significantly higher (p = 0.0001) at 12 and 48 h in relation to both the control and the ATCC strain. However, SAP5 exhibited significantly greater expression at 24 h (p = 0.0001) and decreased expression at 12 and 48 h. Transcriptional genes TEC1 and EFG1 had significantly higher expression levels at 12 h; however, they decreased gradually at 24 h and 48 h compared to both the control and the ATCC strain, suggesting that these genes are important in the initial biofilm formation stage (12 h) but not in the mature biofilms (24 and 48 h). The *BCR1* and *ALS3* genes exhibited similar expression profiles to each other, with a significant increase observed at 12 h and gradual and significant decreases at 24 h and 48 h (p = 0.0001) (Table 3).

Based on these results, we expanded this study for an in vivo model of experimental candidiasis using G. mellonella as a host model. Although both strains were lethal to larvae within 24 h after infection, Ca60 was more pathogenic (p = 0.0394) because it leads to death of the larvae more quickly than ATCC strain as shown in Fig. 3. We also compare the pathogenicity of C. albicans to prime the G. mellonella immune response, evaluating changes in the number of available hemocytes. We tested whether each strain can affect hemocity density at 4, 8 and 12 h post-infection. Hemocyte density for the Ca60 was lower at all times evaluated compared to ATCC strain but was statistically significant only in time 12 h (p = 0.0349; Fig. 4), indicating that this strain is more harmful to the larvae.

Discussion

This study evaluated the CFU/mL of C. albicans cells in biofilms, quantified the expression profiles of the ALS1, ALS3, HWP1, BCR1, EFG1, TEC1, SAP5, PLB2 and LIP9 genes that this yeast uses in the development of diseases and compared the pathogenicity of each strain in G. mellonella model through survival curve and hemocyte counting. Biofilm formation is a complex and sequential process that includes several steps: adhesion of yeast cells to a substrate, proliferation of these cells, formation of hyphae on the most superficial layer of the biofilm, production and accumulation of extracellular matrix and, ultimately, dispersion of these cells [28, 33]. Mature biofilms are far more resistant to both antifungal therapy and the host's immunological factors in comparison with planktonic yeast cells [14]. In vitro assays have become an important tool for understanding the composition and properties of C. albicans biofilms because they provide accurate and reproducible quantification of the viable cells that make up this complex structure [34].

In the present study, the biofilms formation of *C*. *albicans* strains was evaluated using viable cell count (CFU/mL) and qRT-PCR methods. First, the CFU/mL



Fig. 2 Relative quantification (log) of the expression levels of adhesion genes (*ALS1, ALS3* and *HWP1*), transcriptional regulatory genes (*TEC1, BCR1* and *EFG1*) and hydrolase genes (*SAP5, PLB2* and *LIP9*) in the cells of ATCC 18804 (**a**-**c**) and

counts of the two strains tested were evaluated, indicating that the ATCC18804 strain produced a higher CFU/mL compared to the clinical strain. These data suggest that the ATCC18804 strain is more adapted to different in vitro culture methods. Several studies describe the quantification of biofilms formed by *C. albicans* using the CFU/mL method [6, 34–37]. Further, we extended this evaluation to different

Ca60 strains (**d**–**f**) at 12, 24 and 48 h of biofilms formation using qRT-PCR in relation to the control of each strain (0 h time). Values are expressed as the means and standard deviations

24H

24H

24H

48H

-

48H

48H

biofilm formation times (0, 12, 24, 48 h), and our results are in agreement with previous reports of a gradual increase in biomass, even at longer times such as 72 h [19], using the quantitative method of CFU/ mL. The variability observed in the biofilms production kinetics of different *C. albicans* strains when evaluated by various quantification methods maybe due to the origin of the clinical specimen, i.e., the

ALS1

ALS3

HWP1

BCR1 TEC1

EFG1

SAP5

PLB2 LIP9 Table 2Values of relativequantification (log) andstandard deviation for allgenes analyzed in biofilmsof Candida albicansATCC18804

ALS1 1.0 0.98 ± 0.503 0.91 ± 0.216 0.82 ± 0.0279 ALS3 1.0 1.20 ± 0.411 0.67 ± 0.225 0.39 ± 0.157 HWP1 1.0 1.14 ± 0.213 1.27 ± 0.572 1.50 ± 0.533 BCR1 1.0 1.93 ± 1.244 1.47 ± 0.652 0.58 ± 0331 TEC1 1.0 2.80 ± 1.485 2.03 ± 0.978 0.80 ± 0.433 EFG1 1.0 4.08 ± 1.258 3.34 ± 0.880 1.33 ± 1.184 SAP5 1.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP9 1.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB2 1.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 Groups Control 12 h 24 h 48 h ALS1 1.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS3 1.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP1 1.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR1 1.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0632	Groups	Control	12 h	24 h	48 h
ALS31.0 1.20 ± 0.411 0.67 ± 0.225 0.39 ± 0.157 HWP11.0 1.14 ± 0.213 1.27 ± 0.572 1.50 ± 0.533 BCR11.0 1.93 ± 1.244 1.47 ± 0.652 0.58 ± 0331 TEC11.0 2.80 ± 1.485 2.03 ± 0.978 0.80 ± 0.433 EFG11.0 4.08 ± 1.258 3.34 ± 0.880 1.33 ± 1.184 SAP51.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP91.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB21.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 FrequenciesGroupsControl 12 h 24 h48 hALS11.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALS1	1.0	0.98 ± 0.503	0.91 ± 0.216	0.82 ± 0.0279
HWP1 1.0 1.14 ± 0.213 1.27 ± 0.572 1.50 ± 0.533 BCR1 1.0 1.93 ± 1.244 1.47 ± 0.652 0.58 ± 0331 TEC1 1.0 2.80 ± 1.485 2.03 ± 0.978 0.80 ± 0.433 EFG1 1.0 4.08 ± 1.258 3.34 ± 0.880 1.33 ± 1.184 SAP5 1.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP9 1.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB2 1.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 Groups Control 12 h 24 h 48 h ALS3 1.00 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS1 1.0 0.61 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR1 1.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR1 1.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC1 1.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG1 1.0 1.49 ± 0.241 0.6	ALS3	1.0	1.20 ± 0.411	0.67 ± 0.225	0.39 ± 0.157
BCRI 1.0 1.93 ± 1.244 1.47 ± 0.652 0.58 ± 0331 TECI 1.0 2.80 ± 1.485 2.03 ± 0.978 0.80 ± 0.433 EFGI 1.0 4.08 ± 1.258 3.34 ± 0.880 1.33 ± 1.184 SAP5 1.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP9 1.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB2 1.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 Groups Control 12 h 24 h 48 h ALS3 1.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS3 1.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP1 1.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR1 1.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC1 1.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG1 1.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP5 1.0 3.4	HWP1	1.0	1.14 ± 0.213	1.27 ± 0.572	1.50 ± 0.533
TEC1 1.0 2.80 ± 1.485 2.03 ± 0.978 0.80 ± 0.433 EFG1 1.0 4.08 ± 1.258 3.34 ± 0.880 1.33 ± 1.184 SAP5 1.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP9 1.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB2 1.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 Groups Control 12 h 24 h 48 h ALS1 1.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS3 1.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP1 1.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR1 1.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC1 1.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG1 1.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP5 1.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP9 1.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1	BCR1	1.0	1.93 ± 1.244	1.47 ± 0.652	0.58 ± 0331
EFG11.0 4.08 ± 1.258 3.34 ± 0.880 1.33 ± 1.184 SAP51.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP91.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB21.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 GroupsControl12 h24 h48 hALSI1.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 3.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	TEC1	1.0	2.80 ± 1.485	2.03 ± 0.978	0.80 ± 0.433
SAP51.0 0.62 ± 0.317 1.25 ± 0.510 1.32 ± 0.622 LIP91.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB21.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 GroupsControl12 h24 h48 hALS11.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	EFG1	1.0	4.08 ± 1.258	3.34 ± 0.880	1.33 ± 1.184
LIP9 1.0 0.53 ± 0.072 0.91 ± 0.257 1.01 ± 0.659 PLB2 1.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 Groups Control 12 h 24 h 48 h ALS1 1.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS3 1.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP1 1.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR1 1.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC1 1.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG1 1.0 3.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP5 1.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.513 PLB2 1.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	SAP5	1.0	0.62 ± 0.317	1.25 ± 0.510	1.32 ± 0.622
PLB2 1.0 1.02 ± 0.436 1.52 ± 0.709 2.61 ± 0.776 Groups Control 12 h 24 h 48 h ALS1 1.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS3 1.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP1 1.0 16.41 \pm 4.471 27.59 ± 1.812 48.80 \pm 5.831 BCR1 1.0 1.95 \pm 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC1 1.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG1 1.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP5 1.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB2 1.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	LIP9	1.0	0.53 ± 0.072	0.91 ± 0.257	1.01 ± 0.659
GroupsControl12 h24 h48 hALS11.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	PLB2	1.0	1.02 ± 0.436	1.52 ± 0.709	2.61 ± 0.776
GroupsControl12 h24 h48 hALS11.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312					
ALS11.0 0.03 ± 0.008 0.45 ± 0.103 0.41 ± 0.085 ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	Groups	G 1			
ALS31.0 3.81 ± 1.302 2.82 ± 1.114 2.53 ± 0.877 HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312		Control	12 h	24 h	48 h
HWP11.0 16.41 ± 4.471 27.59 ± 1.812 48.80 ± 5.831 BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0.632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALS1	1.0	12 h 0.03 ± 0.008	24 h 0.45 ± 0.103	48 h 0.41 ± 0.085
BCR11.0 1.95 ± 0.535 1.64 ± 0.354 1.66 ± 0632 TEC11.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALSI ALS3	1.0 1.0	12 h 0.03 ± 0.008 3.81 ± 1.302	24 h 0.45 ± 0.103 2.82 ± 1.114	
TECI1.0 2.81 ± 0.402 0.87 ± 0.194 0.54 ± 0.145 EFGI1.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALSI ALS3 HWP1	1.0 1.0 1.0	12 h 0.03 ± 0.008 3.81 ± 1.302 16.41 ± 4.471	24 h 0.45 ± 0.103 2.82 ± 1.114 27.59 ± 1.812	$\begin{array}{r} 48 \text{ h} \\ \\ 0.41 \pm 0.085 \\ 2.53 \pm 0.877 \\ 48.80 \pm 5.831 \end{array}$
EFG11.0 1.49 ± 0.241 0.69 ± 0.057 0.17 ± 0.032 SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALSI ALS3 HWP1 BCR1	1.0 1.0 1.0 1.0 1.0	12 h 0.03 ± 0.008 3.81 ± 1.302 16.41 ± 4.471 1.95 ± 0.535	24 h 0.45 ± 0.103 2.82 ± 1.114 27.59 ± 1.812 1.64 ± 0.354	$\begin{array}{r} 48 \text{ h} \\ \\ 0.41 \pm 0.085 \\ 2.53 \pm 0.877 \\ 48.80 \pm 5.831 \\ 1.66 \pm 0632 \end{array}$
SAP51.0 3.49 ± 0.925 14.86 ± 2.994 12.71 ± 2.242 LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALSI ALS3 HWP1 BCR1 TEC1	1.0 1.0 1.0 1.0 1.0 1.0	$12 h$ 0.03 ± 0.008 3.81 ± 1.302 16.41 ± 4.471 1.95 ± 0.535 2.81 ± 0.402	24 h 0.45 ± 0.103 2.82 ± 1.114 27.59 ± 1.812 1.64 ± 0.354 0.87 ± 0.194	$\begin{array}{r} 48 \text{ h} \\ \hline 0.41 \pm 0.085 \\ 2.53 \pm 0.877 \\ 48.80 \pm 5.831 \\ 1.66 \pm 0632 \\ 0.54 \pm 0.145 \end{array}$
LIP91.0 3.73 ± 1.101 2.404 ± 0.514 6.97 ± 1.551 PLB21.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALSI ALS3 HWPI BCRI TECI EFGI	1.0 1.0 1.0 1.0 1.0 1.0 1.0	$12 h$ 0.03 ± 0.008 3.81 ± 1.302 16.41 ± 4.471 1.95 ± 0.535 2.81 ± 0.402 1.49 ± 0.241	$24 h$ 0.45 ± 0.103 2.82 ± 1.114 27.59 ± 1.812 1.64 ± 0.354 0.87 ± 0.194 0.69 ± 0.057	$48 h$ 0.41 ± 0.085 2.53 ± 0.877 48.80 ± 5.831 1.66 ± 0632 0.54 ± 0.145 0.17 ± 0.032
PLB2 1.0 2.30 ± 0.503 1.30 ± 0.283 3.70 ± 1.312	ALSI ALS3 HWPI BCRI TECI EFGI SAP5	1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	$12 h$ 0.03 ± 0.008 3.81 ± 1.302 16.41 ± 4.471 1.95 ± 0.535 2.81 ± 0.402 1.49 ± 0.241 3.49 ± 0.925	$24 h$ 0.45 ± 0.103 2.82 ± 1.114 27.59 ± 1.812 1.64 ± 0.354 0.87 ± 0.194 0.69 ± 0.057 14.86 ± 2.994	$\begin{array}{c} 48 \text{ h} \\ \\ 0.41 \pm 0.085 \\ 2.53 \pm 0.877 \\ 48.80 \pm 5.831 \\ 1.66 \pm 0632 \\ 0.54 \pm 0.145 \\ 0.17 \pm 0.032 \\ 12.71 \pm 2.242 \end{array}$
	ALSI ALS3 HWPI BCRI TECI EFGI SAP5 LIP9	1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	$12 h$ 0.03 ± 0.008 3.81 ± 1.302 16.41 ± 4.471 1.95 ± 0.535 2.81 ± 0.402 1.49 ± 0.241 3.49 ± 0.925 3.73 ± 1.101	$24 h$ 0.45 ± 0.103 2.82 ± 1.114 27.59 ± 1.812 1.64 ± 0.354 0.87 ± 0.194 0.69 ± 0.057 14.86 ± 2.994 2.404 ± 0.514	$48 h$ 0.41 ± 0.085 2.53 ± 0.877 48.80 ± 5.831 1.66 ± 0632 0.54 ± 0.145 0.17 ± 0.032 12.71 ± 2.242 6.97 ± 1.551

Control: time immediately after adherence (0 h)

Table 3Values of relativequantification (log) andstandard deviation for allgenes analyzed in biofilmsof Candida albicans clinicalstrain 60

Control: time immediately after adherence (0 h)

Fig. 3 *C. albicans* (Ca60) is more pathogenic to *G. mellonella* than ATCC strain. Significant differences were observed between *C. albicans* 60 and *C. albicans* ATCC18804 (log-rank test: p = 0.0394)

100 No Injection Percent survival (%) PBS 80 C. albicans ATCC18804 60 C. albicans 60 40 20 0 0 8 16 24 Time (hours)

strain isolation site and the factors related to the host's ecological niche, the environment in which factors internal and external to the host directly or indirectly influence the virulence of this yeast.

In an attempt to elucidate the mechanisms that contribute to the differentiation of in vitro biofilms production by strains of the same species, we used relative quantification (qPCR) of genes related to this characteristic that are essential for *C. albicans* pathogenesis. Most studies use relative gene expression to quantify genes involved in the virulence of this yeast against adverse environmental conditions, such as types of nutrients used for growth, production of biofilms in vitro and in vivo, presence or absence of inhibitory substances produced by other microorganisms and sensitivity or resistance to antifungal agents [19, 29, 38–40]. Most studies have evaluated relative gene expression in planktonic cells under the same treatment [26, 29, 35–37]; however, the present study evaluated different genes at different in vitro biofilm



Fig. 4 *G. mellonella* hemocytes density decreased with the injection of *C. albicans* 60. The hemolymph was collected to determine the hemocytes densities. Student's *t* test was used to compare hemocytes densities between the *C. albicans* 60 and *C. albicans* ATCC18804 groups. *p = 0.0349

formation times, more closely approximating the conditions in which these yeasts are found in the host.

The capacity to form biofilm has been associated with the presence of transcriptional regulatory genes in C. albicans [7]. Among these genes, we can include BCR1, TEC1 and EFG1 [12-14]. In this study, the ATCC and Ca60 strains differed in the amounts of expression of the TEC1, BCR1 and EFG1 genes. In the ATCC strain, the EFG1 gene was significantly expressed compared to the control at 12 and 24 h, exhibiting higher values than other biofilms genes. TEC1 and BCR1 were positively regulated at 12 h, in accordance with the higher CFU values obtained in this same period. The results for the Ca60 strain were similar in relation to the 12 h time, where the TEC1 gene was upregulated compared to BCR1 and EFG1 and gradually decreasing over the formation times. These findings corroborate previous reports, which describe the upregulation of these transcripts in the formation of in vitro and in vivo biofilms [7, 8]. The heterogenic cell activity of the EFG1 gene allows colonization by different populations of C. albicans against the host's immune system [13]. The BCR1 gene positively stimulates gene expression, producing important cell wall proteins involved in the adhesion to both biotic and abiotic surfaces [11, 12]. In the present study, among all evaluated genes, HWP1 exhibited higher upregulation, being gradually expressed over the biofilm formation times in the Ca60 strain, with an expression level 47.3fold higher than the ATCC strain.

Regarding adhesion genes, *ALS1* exhibited down-regulation in *C. albicans* strains at all analyzed times.

The low expression levels of ALS1 in all strains and different times may be explained by the choice of biofilm development times. According to Yeater et al. [41], ALSI expression levels are influenced by the culture growth stage, and their conclusions on the degree of expression vary according to comparisons adopted in each analysis; however, there is a consensus in the literature confirming the presence of high levels of ALS1 expression during the biofilms development process [7, 29]. ALS3 was upregulated at 12 h in both strains; however, Ca60 achieving 3-fold increase compared the ATCC strain at 24 and 48 h. This gene encodes specific hyphal adhesins [7, 9, 19, 29] and is more expressed when we have higher numbers of filaments. This fact may explain why initial and intermediate biofilms express ALS3 more than mature biofilms, regardless of the substrate [19].

The expression of hydrolases *SAP5*, *PLB2* and *LIP9* was higher to Ca60 compared to ATCC strain at all times, achieving 11.88 and 9.62-fold increase at 24 and 48 h, respectively. These data are in accordance with previous reports that in the presence of filaments, expression of this gene is stimulated [19, 42].

Nailis et al. [19] compared the amounts of *C. albicans* filaments with the expression *HWP1* and all genes of the families *ALS, SAP, LIP* and *PLB* in biofilms formed on abiotic and biotic surfaces at six biofilm development times (1, 12, 24, 48, 72 and 144 h) by means of qPCR. According to the obtained results, the authors concluded that changes in the environment where the biofilms grow may interfere with its filamentation and gene expression.

In order to elucidate the in vitro results obtained through biofilm formation and gene expression, we investigated the pathogenicity of these strains in *G. mellonella* model. Firstly, we tried to verify if there is a difference in the survival assay between the strains. Ca60 was more pathogenic because it leads to death of the larvae more quickly than ATCC strain. These data are similar with previous studies that evaluated the pathogenicity of *C. albicans* in this model [26, 32, 43, 44].

We also explored alterations of hemocyte density between these two strains and we verified that Ca60 was capable to reduce the hemocyte density at all times evaluated compared to ATCC strain but was statistically significant only in time 12 h. The density of circulating hemocyte in the hemolymph of *G. mellonella* may be indicative of infection with low hemocyte intensity associate with infection and high density indicating insect health [45]. These data agree with our in vitro results that showed increased transcriptional profile of strain Ca60 for genes related to hydrolases (*SAP5*, *PLB2* and *LIP9*) and filamentation (*HWP1*) that are essential for the colonization and invasion of yeast in the host tissue.

More complex studies involving several types of clinical specimens isolated from different sites colonized with *C. albicans* are needed to understand and associate different gene expression profiles with pathogenicity factors to seek new treatment options, in addition to providing knowledge at the molecular level of the effects of virulence factors insusceptible hosts. In conclusion, the *C. albicans* strains used in this study differ in the amount of biofilm formation, virulence in vivo and transcriptional profiles of genes analyzed that can change factors associated with colonization, proliferation and survival of *C. albicans* at different niches. *SAP5* and *HWP1* were the genes more expressed in the formation of biofilm in vitro.

Acknowledgements We acknowledge the São Paulo Council of Research—FAPESP, Brazil (Grants 2011/15194-0, 2012/15250-0 and 2012/02184-9) for supporting this research.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflict of interest.

References

- Colombo AL, Guimarães T, Camargo LFA, et al. Brazilian guidelines for the management of candidiasis: a joint meeting report of three medical societies. Braz J Infect Dis. 2013;17:283–312.
- Mayer LF, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119–28.
- Agwu E, Ihongbe JC, McManus BA, et al. Distribution of yeast species associated with oral lesions in HIV-infected patients in Southwest Uganda. Med Mycol. 2012;50:276–80.
- Eggimann P, Garbino J, Pittet D. Epidemiology of *Candida* species infections in critically non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702.
- Hube B. From comensal to pathogen: stage-and tissuespecific gene expression of *Candida albicans*. Curr Opin Microbiol. 2004;7:336–41.
- Hasan F, Xess I, Wang X, Jain N, Fries BC. Biofilm formation in clinical *Candida* isolates and its association with virulence. Microbes Infect. 2009;11:753–61.
- 7. Finkel JS, Mitchell AP. Genetic control of *Candida albicans* biofilm development. Nat Rev Microbiol. 2011;9:109–18.

- 8. Fox PE, Nobile JC. A sticky situation: untangling the transcriptional network controlling biofilm development in *Candida albicans*. Transcription. 2012;3:315–22.
- Nobile CJ, Mitchell AP. Regulation of cell surface genes and biofilm formation by the *C. albicans* transcription factor Bcr1p. Curr Biol. 2005;15:1150–5.
- Nobile CJ, Mitchell AP. Genetics and genomics of *Candida* albicans biofilm formation. Cell Microbiol. 2006;8: 1382–91.
- Nobile CJ, Andes DR, Nett JE, et al. Critical role of Bcr1dependent adhesins in *C. albicans* biofilm formation in vitro and in vivo. PLoS Pathog. 2006;2:e63.
- 12. Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in *Candida albicans*. Cell. 2012;148:126–38.
- Pierce VJ, Kumamoto AC. Variation in *Candida albicans* EFG1 expression enables host-dependent changes in colonizing fungal populations. MBio. 2012;3:e00117-12.
- Fanning S, Xu W, Solis N, Woolford CA, et al. Divergent targets of *Candida albicans* biofilm regulator Bcr1 in vitro and in vivo. Eukar Cell. 2012;11:896–904.
- Naglik JR, Rodgers CA, Shirlaw PJ, et al. Differential expression of *Candida albicans* secreted aspartyl proteinase and phospholipase B genes in human correlates with active oral and vaginal infections. J Infect Dis. 2003;188:469–79.
- Naglik JR, Challacombe SJ, Hube B. *Candida albicans* aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol. 2003;67:400–28.
- Naglik JR, Albrecht A, Bader O, Hube B. *Candida albicans* proteinases and host/pathogen interactions. Cell Microbiol. 2004;6:915–26.
- Naglik JR, Moyes D, Makwana J, et al. Quantitative expression of the *Candida albicans* secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology. 2008;154:3266–80.
- Nailis H, Kucharíková S, Řičicová M, et al. Real- time PCR expression profiling of genes encoding potential virulence factors in *Candida albicans* biofilms: identification of model-dependent and -independent gene expression. BMC Microbiol. 2010;10:114.
- Chamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infect Dis. 2007;7:42–55.
- Arvantis M, Glavis-Bloom J, Mylonakis E. *C.elegans* for anti-infective discovery. Curr Opin Pharmacol. 2013;13: 769–74.
- 22. Fedhila S, Buisson C, Dussurget O, et al. Comparative analysis of the virulence of invertebrate and mammalian pathogenic bacteria in the oral insect infection model *Galleria mellonella*. J Invertebr Pathol. 2010;103:24–9.
- Chibebe Junior J, Fuchs BB, Sabino CP, et al. Photodynamic and antibiotic therapy impair the pathogenesis of *Enterococcus faecium* in a whole animal insect model. PLoS ONE. 2013;8(2):e55926.
- Chibebe Junior J, Sabino CP, Tan X, et al. Selective photoinactivation of *Candida albicans* in the non-vertebrate host infection model *Galleria mellonella*. BMC Microbiol. 2013;13:217.
- Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog. 2012;8:e1002585.

- 26. Junqueira JC, Fuchs BB, Muhammed M, et al. Oral *Candida albicans* from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive *Candida* isolates. BMC Microbiol. 2011;4:247.
- Seneviratne CJ, Silva WJ, Jin LJ, et al. Architectural analysis, viability assessment and growth kinetics of *Candida albicans* and *Candida glabrata* biofilms. Arch Oral Biol. 2009;54:1052–60.
- Costa ACBP, Pereira AC, Freire F, et al. Methods for obtaining reliable and reproducible results in studies of *Candida biofilms* formed in vitro. Mycoses. 2013;56: 614–22.
- Nailis H, Coenye T, Van Nieuwerburgh F, et al. Development ment and evaluation of different normalization strategies for gene expression studies in *Candida albicans* biofilms by real- time PCR. BMC Mol Biol. 2006;4:7–25.
- Hnisz D, Bardet AF, Nobile CJ, et al. A Histone deacetylase adjusts transcription kinetics at coding sequences during *Candida albicans* morphogenesis. PLoS Genet. 2012;8: e1003118.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
- Cotter G, Doyle S, Kavanagh K. Development of an insect model for the in vivo pathogenicity testing of yeasts. FEMS Immunol Med Microbiol. 2000;27:163–9.
- Kumamoto CA. Candida biofilms. Curr Opin Microbiol. 2002;5:608–11.
- 34. Taff HT, Nett JE, Andes DR. Comparative analysis of *Candida* biofilm quantitation assays. Med Mycol. 2012;50:214–8.
- Ramage G, VandeWalle K, Wickes LB, López RJC. Characteristics of biofilm formation by *Candida albicans*. Rev Iberoam Micol. 2001;18:163–70.

- Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot Cell. 2005;4:633–8.
- Sánchez-Vargas LO, Estrada-Barraza D, Pozos-Guillen AJ, Rivas-Caceres R. Biofilm formation by oral clinical isolates of *Candida* species. Arch Oral Biol. 2013;58:1318–26.
- Ding X, Liu Z, Su J, Yan D. Human serum inhibits adhesion and biofilm formation in *Candida albicans*. BMC Microbiol. 2014;14:80.
- Buu LM, Chen YC. Impact of glucose levels on expression of hypha-associated secreted aspartyl proteinases in *Candida albicans*. J Biomed Sci. 2014;21:22.
- 40. Semlali A, Killer K, Alanazi H, Chmielewski W, et al. Cigarette smoke condensate increases *C. albicans* adhesion, growth, biofilm formation, and *EAP1*, *HWP1* and *SAP2* gene expression. BMC Microbiol. 2014;14:61.
- Yeater KM, Chandra J, Cheng G, et al. Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology. 2007;153:2373–85.
- 42. Samaranayake YH, Cheung BPK, Yau JYY, et al. Human serum promotes *Candida albicans* biofilm growth and virulence gene expression on silicone biomaterial. PLoS ONE. 2013;8:e62902.
- 43. Vilela SF, Barbosa JO, Rossoni RD, et al. *Lactobacillus acidophilus* ATCC 4356 inhibits biofilm formation by *C. albicans* and attenuates the experimental candidiasis in *Galleria mellonella*. Virulence. 2015;6:29–39.
- 44. Rossoni RD, Barbosa JO, Vilela SFG, et al. Competitive Interactions between *C. albicans*, *C. glabrata* and *C. krusei* during biofilm formation and development of experimental Candidiasis. PLoS ONE. 2015;10:e0131700.
- 45. Bergin D, Brennan M, Kavanagh K. Fluctuations in haemocyte density and microbial load may be used as indicators of fungal pathogenicity in larvae of *Galleria mellonella*. Microbes Infect. 2003;5:1389–95.